ash 2014: phase ii/iii study of lenalidomide in relapsed/refractory diffuse large b-cell lymphoma
Published 9 years ago • 206 plays • Length 4:49Download video MP4
Download video MP3
Similar videos
-
5:51
ash 2014: phase ii sprint study of lenalidomide in relapsed/refractory mantle cell lymphoma
-
5:52
ash 2014: phase ii sprint study of lenalidomide in relapsed/refractory mantle cell lymphoma
-
4:34
ash 2014: phase ii study of lenalidomide plus rituximab for mantle cell lymphoma (part 1)
-
4:38
ash 2014: phase ii study of lenalidomide plus rituximab for mantle cell lymphoma (part 1)
-
1:51
ash 2014: novel biologic therapies for managing non-hodgkin lymphoma
-
2:48
ash 2014: phase ii study of lenalidomide plus rituximab for mantle cell lymphoma (part 2)
-
2:46
ash 2014: phase ii study of lenalidomide plus rituximab for mantle cell lymphoma (part 2)
-
6:37
l-mind trial in relapsed/refractory dlbcl
-
3:00
ash 2014: phase ii trial of interim pet scan-tailored therapy in diffuse large b-cell lymphoma
-
1:14
ash 2014: managing diffuse large b-cell lymphoma
-
46:48
relapsed and refractory diffuse large b-cell lymphoma
-
1:26
ash 2014: phase i study of duvelisib in indolent non-hodgkin lymphoma
-
1:48
mor208 plus lenalidomide in r-r diffuse large b-cell lymphoma
-
2:07
relapsed/refractory diffuse large b-cell lymphoma
-
2:04
ash 2014: recent investigational advances in mantle cell lymphoma treatment
-
1:12:05
relapsed / refractory diffuse large b-cell lymphoma (dlbcl) with dr gareth gregory
-
1:54
bispecifics for relapsed/refractory diffuse large b-cell lymphoma (r/r dlbcl)- blood cancers onctalk
-
3:26
phase ii study of acalabrutinib, lenalidomide & rituximab for high tumor burden follicular lymphoma
-
1:31
long-term outcomes with tafasitamab plus lenalidomide for r/r dlbcl